Background Comorbidities are common among people with multiple sclerosis (PwMS); yet,
their impact on the cost-of-illness (COI) in MS is unknown. Objective Explore the …

Introduction Several disease-modifying therapies (DMTs), covering a broad spectrum of
mechanisms of action, have been approved by regulatory agencies for the treatment of …

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Background Initiation of immunomodulators in patients experiencing a clinically isolated
syndrome (CIS) may delay progression to clinically definite MS. However, lack of consensus …

Background: Little is known about changes in the costs of illness (COI) among multiple
sclerosis (MS) patients during recent years. Objectives: To compare the COI among MS …

Objectives More information are needed on the prevalence of different Multiple Sclerosis
(MS) phenotypes and their treatment management. This study assessed the prevalence and …

Purpose The aim of this study was to describe the treatment journey of patients with multiple
sclerosis (MS). Methods This study was conducted in 2 phases. The first consisted of a …

Background Medical therapy for multiple sclerosis (MS) is expensive. Quantifying the burden
of MS is fundamental for health-care planning and the allocation of resources for the …

In the past 5 years, the combination of developments in diagnostic strategy and approval of
new disease-modifying therapies has provided an opportunity to achieve dramatic …